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Abstract
Triglyceride content in the liver is regulated by the uptake, production and elimination of
lipoproteins, and derangements in these processes contribute to nonalcoholic fatty liver
disease (NAFLD). Previous studies show a direct relationship between intrahepatic fat and
production of apolipoprotein B100 (apoB100) containing particles, VLDL and LDL, but little
consensus exists regarding changes in lipoprotein production in the development of simple
steatosis (SS) versus nonalcoholic steatohepatitis (NASH). Further, ethnic variations in
lipoproteins among SS and NASH are unknown as is how such variations might contribute
to the differential prevalence of disease among Caucasians versus African Americans. In
this study, we assessed plasma lipoprotein profiles by nuclear magnetic resonance (NMR)
spectroscopy in 70 non-diabetic class III obese females recruited from the surgical weight
loss clinic. Of these, 51 females were stratified by biopsy-staged NAFLD severity (histolog-
ically normal, SS, or NASH). NASH females displayed increased circulating triglycerides
and increased VLDL particle number and size relative to those with histologically normal
livers, while total and large LDL concentration decreased in SS versus NASH and corre-
lated with increased insulin resistance (via HOMA2-IR). When Caucasian women were
examined alone (n = 41), VLDL and triglycerides increased between normal and SS, while
total LDL and apoB100 decreased between SS and NASH along with increased insulin
resistance. Compared to Caucasians with SS, African American women with SS displayed
reduced triglycerides, VLDL, and small LDL and a more favorable small to large HDL ratio
despite having increased BMI and HOMA2-IR. These findings suggest that ApoB100 and
lipoprotein subclass particle number and size can delineate steatosis from NASH in obese
Caucasian females, but should be interpreted with caution in other ethnicities as African
Americans with SS display relatively improved lipoprotein profiles. This may reflect
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Introduction
Hepatic steatosis stems from an imbalance between lipid supply and demand where excess
fatty acids are stored in the liver as fat [1]. Obese individuals in particular have surplus fatty
acids and increased hepatic steatosis due to dietary intake and the tendency to become insulin
resistant. With decreased insulin sensitivity, insulin can no longer inhibit lipolysis in peripheral
tissues, resulting in more circulating free fatty acids for potential storage in the liver [2]. Once
accumulated, hepatic triglyceride (TG) is eliminated from the liver via lipid oxidation or the
secretion of TG-rich very-low density lipoproteins (VLDL) depending on local or peripheral
energy needs [3, 4]. However, this lipid and lipoprotein balance can become perturbed in the
setting of obesity and type 2 diabetes (T2D), and may contribute to the development of nonal-
coholic fatty liver disease (NAFLD) [5].
NAFLD encompasses a spectrum of disease ranging from excess fat in more than 5% of
hepatocytes (termed simple steatosis; SS) to nonalcoholic steatohepatitis (NASH), an advanced
inflammatory phenotype hallmarked by hepatocyte ballooning and necrosis [6]. NAFLD, espe-
cially NASH, is associated with hepatic and global metabolic dysfunction, including increased
insulin resistance [5]. While over 25% of the general population has NAFLD, this number
jumps to 90% in class III obese subjects (BMI 40) and to 100% in those with T2D [7, 8]. The
prevalence of the disease differs among ethnicities, with African Americans exhibiting a lower
prevalence of steatosis and NASH relative to Caucasians and Hispanics [8, 9]. Elevated levels of
TG, VLDL and small dense low-density lipoprotein (LDL) and decreased levels of high-density
lipoprotein (HDL) are associated with the development of cardiovascular disease and diabetes.
[3, 10]. Interestingly, African Americans exhibit lower levels of TG and higher levels of HDL
for a given BMI and degree of insulin resistance [11]. However, it is unclear how lipoproteins
vary in SS versus NASH of any ethnicity, with some studies reporting increased production of
VLDL and LDL in NASH relative to SS while others report a decline [12–17].
In this study, we examined lipoprotein profile differences among class III obese females
with histologically-determined SS or NASH and compare them to lipoprotein profiles from
histologically normal-weight-matched female controls. We found distinct differences in lipo-
protein and lipid profiles that may aid in noninvasively determining NAFLD diagnoses and
severity progression [12, 17–19].
Materials and Methods
Subjects
The Internal Review Board of Vanderbilt University approved this study which is registered at
ClinicalTrials.gov (NCT00983463). All studies met NIH and institutional guidelines for
human subject research and the Declaration of Helsinki. All subjects gave informed written
consent prior to participation. Caucasian and African American Class III obese females
(BMI> 40 kg/m2) scheduled for bariatric surgery were recruited from the Vanderbilt Center
for Surgical Weight Loss (Nashville, TN). Inclusion criteria included non-sedentary, non-dia-
betic women between the ages of 23 and 60 years. Screening included anthropomorphic mea-
sures, clinical history, physical exam, and laboratory tests including complete blood count with
differential, liver function tests, and fasting blood glucose. Ethnicity was self-reported.
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Exclusion criteria included presence of viral hepatitis, autoimmune hepatitis, hemochromato-
sis, significant alcohol use (>14 drinks per week over a 2-year period), intercurrent infections
or cancer, previous gastric, duodenal, proximal jejunum or pancreatic resection surgery, and
positive serum pregnancy test. Lean females (BMI 27 kg/m2) were recruited from the Van-
derbilt community and had no significant past medical history. Liver biopsies were not avail-
able for these women as it is discouraged to obtain non-clinically indicated liver biopsies due to
the risks associated with the procedure. Further, we did not utilize AST and ALT to screen for
liver disease in control patients given the values are not sensitive enough to screen for NAFLD
nor are they a reliable indicative of liver disease severity [20–22].
Blood and tissue sampling
Women were studied after an overnight fast (10 hours). Blood was collected from lean
patients by the laboratory nurse practitioner in the morning following an overnight fast. Blood
was collected from patients receiving bariatric surgery preoperatively prior to induction of
anesthesia. The attending surgeon performed intra-operative wedge liver biopsies collected
from the left lobe of the liver for these patients as well.
Plasma analyses
Plasma glucose concentration was determined using an automated glucose analyzer (YSI 2300
STAT plus, Yellow Spring Instrument Co., Yellow Springs, OH, USA). Plasma insulin concen-
trations were measured by radioimmunoassay (Linco Research, St. Louis, MO, USA). Plasma
insulin and glucose were used to calculate insulin resistance using the Homeostatic Model
Assessment of Insulin Resistance with physiologic adjustments (HOMA2-IR) [23]. Hospital
lab services assessed aspartate transaminase (AST) and alanine transaminase (ALT) in surgical
patients via enzymatic methods, albumin via a bromo-cresol green albumin assay, and platelets
via Sysmex Automated Hematology System (Sysmex America, Lincolnshire, IL. USA).
Lipoprotein subclass concentration and particle size were assessed via NMR (nuclear mag-
netic resonance) spectroscopy (Liposcience/LabCorp, Raleigh, NC, USA) using the Lipopro-
file-3 algorithm. Concentrations (nanomoles/L) of total VLDL, LDL, HDL and the following
subclasses were determined according to particle size (nanometers, nm): large VLDL (>60.0
nm), medium VLDL (42.0–60.0 nm), small VLDL (29.0–42.0 nm), IDL (23.0–29.0 nm), large
LDL (20.5–23.0 nm), small LDL (18.0–21.2 nm), large HDL (9.4–14.0 nm), medium HDL
(8.2–9.4 nm) and small HDL (7.3–8.2 nm) [24]. Weighted average particle size for VLDL, LDL,
and HDL was calculated based on subclass concentration and associated diameters. NMR cal-
culated lipid levels highly correlate with respective chemically measured levels of plasma tri-
glyceride (r>0.9), HDL cholesterol (r>0.9), and LDL cholesterol (r = ~0.8–0.9) while
providing the added benefit of quantifying particle concentrations and size [25]. Because each
VLDL and LDL possesses one apolipoprotein B100 (apoB100) molecule, previous methods
used a combination of centrifugation and apoB100 quantification assays to separate and quan-
tify the lipid classes. NMR-derived levels strongly correlate with these methods (r = 0.928) as
well as LDL and HDL levels determined by gradient gel electrophoresis (r = 0.946 and
r = 0.953)[24].
In addition, we employed a novel means of describing insulin sensitivity. Classically, insulin
resistance is defined by the degree of insulin’s effect on glucose metabolism, but several investi-
gators have emphasized the importance of lipid abnormalities in the pathogenesis of insulin
resistance [26, 27]. NMR studies suggest a more “lipocentric” view of insulin resistance after
finding significant associations between specific lipoprotein profile constituents and insulin
resistance [28, 29]. The 6 parameters most associated with insulin resistance include: increased
Lipoproteins in Caucasian and African AmericanWomen with NAFLD
PLOSONE | DOI:10.1371/journal.pone.0142676 November 23, 2015 3 / 17
number of individual particles of large VLDL and small LDL, decreased number of large HDL
particles, bigger VLDL sizes and smaller LDL and HDL overall sizes. Shalaurova and Otvos
et al. used this information to create an equation that can use lipoprotein profiles to describe
insulin sensitivity based on each parameter’s individual association with insulin resistance.
This Lipoprotein Insulin Resistance (LP-IR) Index or Score assigns each lipid parameter an
individual weight as follows: VLDL size, 32; large VLDL, 22; HDL size, 20; large HDL, 12; small
LDL, 8; and LDL size, 6. The sum of these weights creates the LP-IR score, which ranges from
1–100, with 100 being the most insulin resistant [30]. The scores were calculated by the
Liposcience group during NMR analysis, and the algorithm used is described in detail in the
manuscript by Shalaurova and Otvos et al. [30].
Histopathologic Determination of NAFLD Severity
Diagnosis of normal, simple steatosis, or steatohepatitis pathology was made by retrospective
chart review of pathology reports for the liver biopsies collected at the time of surgery by the
attending. Women were diagnosed as having simple steatosis when fat was present in greater
than 5% hepatocytes or NASH if the pathologist described the sample as “steatohepatitis”
based on the degree of lobular inflammation and ballooning [31]. Of note, the current investi-
gators were able to secure slides for 31 of the 51 women in the study in order to evaluate the
biopsies via the NAFLD Activity SCORE (NAS) (Table A in S1 File) and confirm hepato-
pathologist findings with the help of an independent hepatopathologist. The NAS Score is a
sum of independent scores for ballooning, lobular inflammation and steatosis [32]. Women
with a NAS score of 0–1 were categorized as “normal,” 2–3 as “simple steatosis” (SS) 4 or above
as “NASH”. Fibrosis was scored as an independent variable. Unfortunately, due to the retro-
spective nature of this study, slides were not available for all samples. Because of this, we ulti-
mately elected to classify livers based on the original histopathological classification at the time
of surgery that was recorded in the electronic medical record, as this classification was uni-
formly determined and available for all women.
Statistics
Results for two groups were compared by unpaired, two-tailed Mann-Whitney test (t-test)
using Prism 5 (Graphpad Software). Differences among three groups were analyzed by analysis
of variance (ANOVA) when variables were normally distributed by the Kolmogorov-Smirnov
test or upon log transformation. All data are presented as mean ± standard error (SEM). Statis-
tical significance was established at P-value 0.05. Regression analyses (Table B in S1 File)
were used to estimate linear relationships among variables after log transformation of skewed
data.
Results
Anthropometric Measurements in Class III Obese
Lipoprotein profiles consisting of VLDL, IDL, LDL and HDL concentration and particle size
(Fig 1) from 70 class III obese females undergoing bariatric surgery and 9 lean female subjects
were measured by H-NMR spectroscopy. Of our 70 class III obese females, 54 were Caucasian
and 16 were African American. While the cohorts did not differ in demographics such as body
weight, BMI, or insulin sensitivity, African American women exhibited a significant reduction
in liver enzymes (Table 1). When lipid profiles were compared, African Americans exhibited a
less atherogenic lipoprotein profiles including decreased levels of triglycerides, VLDL, and
small LDL as well as improved LDL and HDL size ratios (Table 2).
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Liver histology reports were available for 51 women (41 Caucasians and 10 African Ameri-
cans). Class III obese females were stratified into subcohorts based on liver biopsy-determined
NAFLD diagnoses of histologically normal (non-steatotic; n = 18), simple steatosis (SS;
n = 16), or NASH (n = 17) via NAFLD Activity Score (NAS) and histological determination by
pathologist as simple steatosis or steatohepatitis. Weight, BMI, and fasting glucose levels were
similar across the three obese groups. NASH females were slightly older and exhibited
increased levels of AST, ALT and fasting insulin, and insulin resistance per HOMA2-IR, but
these results were adjusted for age (Table 3). Histology was not available for lean women, but
Fig 1. Schematic illustrating lipoproteins particles under investigation in this study.
doi:10.1371/journal.pone.0142676.g001
Table 1. Baseline characteristics of class III obese females stratified by ethnicity.
Caucasian African Americans P-value
n 54 16
Age 43.4 ± 1.2 39.5 ± 2.2 0.116
Weight (kg) 117.3 ± 2.4 122.0 ± 6.0 0.711
BMI (kg/m2) 43.8 ± 0.8 43.9 ± 2.0 0.566
Insulin (μU/mL) 22.9 ± 1.7 19.9 ± 2.7 0.426
Glucose (mg/dL) 102 ± 2.7 98.2 ± 7.1 0.121
HOMA2-IR (AU) 2.9 ± 0.2 2.5 ± 0.3 0.365
AST (normal range: 0–65 U/mL) 29.3 ± 3.1 18.7 ± 1.4 0.074
ALT (normal range: 0–65 U/mL) 33.2 ± 3.0 15.8 ± 0.9 0.003*
Alkaline Phosphatase (U/L) 80.5 ± 3.0 82.4 ± 6.3 0.857
Albumin (g/dL) 4.1 ± 0.04 4.1 ± 0.1 0.624
Platelets (1000/mm3) 276.1 ± 7.9 282.2 ± 9.8 0.632
Bilirubin (mg/dL) 0.5 ± 0.03 0.4 ± 0.03 0.874
*Statistically significant changes; Data presented as mean ± SEM. AU, arbitrary units. BMI, body mass index; HOMA2-IR, updated homeostasis model
assessment of insulin resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NAS, NAFLD Activity Score.
doi:10.1371/journal.pone.0142676.t001
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demographics and lipoprotein profiles were compared to obese individuals with normal
histology.
Lipoprotein Profiles in Class III ObeseWomen by Histology
Compared to lean females, obese females with normal histology had an elevated HOMA2-IR,
driven by increased fasting glucose and insulin levels (Table 3). Obese women with normal
liver histology were more insulin resistant and had a more atherogenic lipid profile than lean
females manifest by increased large and medium VLDL, increased total and small LDL, and
increased small to large HDL ratio (Table 4). The Lipoprotein Insulin Resistance Score (LP-IR)
was also elevated in the pathologically normal women compared to leans.
Among obese women in the cohort with NAFLD, NASH patients exhibited higher
HOMA2-IR driven primarily by a significant increase in fasting insulin compared to SS and
normal females. Further, NMR determined lipoprotein profiles differed across histology.
NASH females had significantly elevated levels of triglycerides, VLDL cholesterol, large VLDL
particle number, and VLDL size compared to normal and SS females (Table 4). Women with
Table 2. Lipid and lipoprotein measures in class III obese females stratified by ethnicity.
Caucasian African American P-value
n 54 16
NMR calculated lipids
Triglycerides (mg/dL) 157.7 ± 7.5 78.3 ± 4.7 < 0.001*
HDL cholesterol (mg/dL) 44.3 ± 1.2 51.9 ± 4.0 0.049*
VLDL & chylomicron TG (mg/dL) 123.5 ± 7.4 44.0 ± 3.9 < 0.001*
Triglycerides/HDL-C ratio 4.2 ± 0.2 1.7 ± 0.5 < 0.001*
Lipoprotein particles
TOTAL VLDL (nmol/L) 71.4 ± 4.0 30.6 ± 3.3 < 0.001*
Large VLDL & chylomicrons 8.3 ± 0.7 2.0 ± 0.3 < 0.001*
Medium VLDL 26.7 ± 2.4 8.1 ± 1.3 < 0.001*
Small VLDL 36.3 ± 2.1 20.5 ± 2.9 < 0.001*
TOTAL LDL (nmol/L) 1,256 ± 57.7 1,083 ± 69.2 0.134
IDL 118.8 ± 12.3 85.1 ± 10.7 0.235
Large LDL 348 ± 35 566 ± 77 0.012*
Small LDL 789 ± 47 431 ± 77 0.001*
TOTAL HDL (μmol/L) 33.9 ± 0.8 33.3 ± 1.4 0.897
Large HDL 3.7 ± 0.2 6.6 ± 1.0 0.007*
Medium HDL 7.7 ± 0.7 9.1 ± 1.4 0.407
Small HDL 20.4 ± 0.8 16.4 ± 1.1 0.015
ApoB100 (mg/dL) 113.7 ± 3.7 96.1 ± 7.8 0.063
Lipoprotein particle size (nm)
VLDL 53.9 ± 0.9 47.0 ± 1.8 0.001*
LDL 20.4 ± 0.1 20.8 ± 0.1 0.011*
HDL 8.9 ± 0.04 9.3 ± 0.1 0.005*
Particle ratios
LDL small/large ratio 4.8 ± 0.8 2.6 ± 1.4 0.004*
HDL small/large ratio 6.5 ± 0.5 3.7 ± 0.7 0.001*
Lipoprotein Insulin Resistance Score 67.1 ± 2.6 37.6 ± 3.1 < 0.001*
*Statistically significant changes; Data presented as mean ± SEM. AU, arbitrary units.
doi:10.1371/journal.pone.0142676.t002
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SS had increased large LDL levels relative to normal females, while NASH patients interestingly
had decreased large LDL levels. LP-IR was elevated in obese NASH relative to the obese with
normal histology. There were no differences in HDL particle number, LDL size, HDL size, or
ApoB100 concentration in the obese cohort as a whole. We also examined the potential associ-
ation between lipoprotein measures and NAS using linear regression with NAS score as out-
come and lipoprotein measure as predictor. Other adjusted clinical variables include age, race,
weight and BMI. VLDL size, large VLD concentration as well as serum AST, LP-IR, ALT, TG
were found to be positively associated with NAS score. LDL size was found to be inversely asso-
ciated with NAS score. Furthermore, we also examined the association between each individual
component of NAS and lipoprotein measures. The full results of this analysis can be viewed in
data in Table B in S1 File.
Impact of Cohort Selection on Lipoprotein Profiles in NAFLD
When the 41 female Caucasians with NAFLD were examined without the African Americans
in the cohort, additional differences in lipoprotein profiles across pathology emerged compared
to those seen in the cohort as a whole. In the Caucasian cohort, 17 had NASH, 11 had SS, and
13 had normal liver histology (Table 5). Caucasian women with SS showed significant increases
in TG concentration, VLDL concentration, and VLDL size versus normal histology (Table 4).
However, women with NASH demonstrated a decline in TG and VLDL concentrations relative
Table 3. Baseline characteristics of class III obese females stratified by histology.
Leans Obese Normal Obese SS Obese NASH P-Value
n 9 18 16 17 -
Gender (F/M) 9/0 18/0 16/0 17/0 -
Caucasian/African American 7/2 13/5 5-Nov 17/0 -
Age 40.2 ± 2.0 38.8 ± 1.4 43.7 ± 2.9 47.2 ± 6.3b 0.009
Weight (kg) 59.5 ± 2.2**** 122.7 ± 5.2 116.0 ± 4.7 116.8 ± 2.9 0.553
BMI (kg/m2) 22.5 ± 0.8**** 45.4 ± 1.3 43.1 ± 1.3 43.9 ± 1.6 0.400
Fasting insulin (μU/mL) 7.6 ± 1.0**** 18.7 ± 1.8 20.3 ± 3.2 28.8 ± 3.5a 0.026
Fasting glucose (mg/dL) 81.6 ± 1.9*** 96.4 ± 2.6 102.9 ± 6.5 109.8 ± 6.2 0.241
HOMA2-IR (AU) 0.9 ± 0.2*** 2.4 ± 0.2 2.5 ± 0.4 3.7 ± 0.4c 0.018
AST (normal range: 0–65 U/mL) - 20.2 ± 1.5 26.5 ± 3.5 46.6 ± 9.0a 0.022
ALT (normal range: 0–65 U/mL) - 22.3 ± 2.7 29.3 ± 4.9 49.2 ± 7.1b 0.009
Alkaline Phosphatase (U/L) - 72.6 ± 5.0 91.1 ± 7.0 82.3 ± 4.3 0.271
Albumin (g/dL) - 4.1 ± 0.1 4.2 ± 0.1 4.1 ± 0.1 0.936
Bilirubin (mg/dL) - 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.532
NAS - 0.8 ± 0.2 2.7 ± 0.3a 5.0 ± 0.2d <0.001
Data presented as mean ± SEM. AU, arbitrary units. Asterisks represent significant difference between lean and obese:
***P<0.001
****P<0.0001
One-way ANOVA P values among obese groups (far-right). Dunn’s Multiple Comparison test results for obese group:
aP <0.05 vs. normal
bP <0.01 vs. normal
cP <0.05 vs. SS
dP <0.001 vs. normal
Abbreviations: BMI, body mass index; HOMA2-IR, updated homeostasis model assessment of insulin resistance; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; NAS, NAFLD Activity Score.
doi:10.1371/journal.pone.0142676.t003
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to SS females, and this was accompanied by significant reductions in total LDL and apoB100
particle numbers (Table 4). Simultaneously, there were increases in HOMA2-IR and insulin in
NASH versus SS, and elevated LP-IR in NASH versus normal.
Interestingly, despite enrolling every African American woman who came through clinic
during our proposed study period, none of the females had a diagnosis of NASH. In this small
African American cohort, 5 had SS and 5 had non-steatotic normal liver histology. There were
no differences in demographics or lipoprotein profiles (Table 6) between the groups.
Table 4. Lipid and lipoprotein measures in class III obese females stratified by histology.
Variable Lean Obese Normal Obese SS Obese NASH P-value
n 9 18 16 17
NMR calculated lipids
Triglycerides (mg/dL) 76.9 ± 2.9*** 119.0 ± 12.9 157.0 ± 18.8 168.2 ± 9.9a 0.017
HDL cholesterol (mg/dL) 60.6 ± 4.2* 45.3 ± 2.6 51.0 ± 4.2 44.8 ± 1.8 0.58
VLDL & chylomicron TG (mg/dL) 42.9 ± 4.1*** 85.1 ± 13.1 115.7 ± 17.4 136.8 ± 10.2a 0.016
Triglycerides/HDL-C ratio 1.3 ± 0.1**** 2.8 ± 0.4 3.5 ± 0.6 3.9 ± 0.3 0.081
Lipoprotein particles
TOTAL VLDL (nmol/L) 34.9 ± 4.0** 52.7 ± 8.5 63.5 ± 8.7 72.5 ± 5.6 0.165
Large VLDL & chylomicrons 1.0 ± 0.2*** 4.7 ± 0.9 8.2 ± 1.4 10.4 ± 1.0b 0.002
Medium VLDL 7.4 ± 1.8** 11.2 ± 2.5 23.2 ± 4.8 25.3 ± 2.8 0.254
Small VLDL 26.5 ± 3.2 22.4 ± 2.6 32.1 ± 4.6 36.7 ± 3.2 0.109
TOTAL LDL (nmol/L) 853 ± 117** 1,177 ± 76 1,487 ± 101a 1,157 ± 141 0.05
IDL 104 ± 18 111 ± 17 140. ± 29 102 ± 15 0.839
Large LDL 675 ± 114* 457 ± 69 527 ± 73 264 ± 62c 0.018
Small LDL 72 ± 12**** 608 ± 90 820 ± 115 789 ± 75 0.379
TOTAL HDL (μmol/L) 35.3 ± 1.7 31.7 ± 1.1 35.7 ± 1.9 35.2 ± 1.4 0.168
Large HDL 9.2 ± 0.9**** 5.0 ± 0.7 5.2 ± 1.0 3.6 ± 0.4 0.452
Medium HDL 17.1 ± 1.6*** 7.2 ± 1.1 6.9 ± 1.0 7.2 ± 1.1 0.979
Small HDL 9.0 ± 1.6**** 17.5 ± 1.3 20.9 ± 1.6 21.6 ± 1.3 0.066
ApoB100 (mg/dL) - 106.2 ± 5.1 120.8 ± 7.5 103.6 ± 6.1 0.127
Lipoprotein particle size (nm)
VLDL 43.5 ± 0.7*** 50.4 ± 1.1 54.0 ± 2.2 57.3 ± 1.1b 0.003
LDL 21.3 ± 0.1*** 20.6 ± 0.1 20.6 ± 0.2 20.2 ± 0.1 0.053
HDL 9.8 ± 0.1**** 9.1 ± 0.1 8.9 ± 0.1 8.9 ± 0.1 0.668
Particle ratios
LDL small/large ratio 0.1 ± 0.0**** 3.9 ± 1.5 3.9 ± 1.9 5.6 ± 1.1 0.047
HDL small/large ratio 1.1 ± 0.3**** 4.9 ± 0.8 6.0 ± 1.0 6.9 ± 0.9 0.286
Lipoprotein Insulin Resistance Score 13.4 ± 1.7**** 51.8 ± 5.3 63.2 ± 6.1 73.4 ± 2.8a 0.021





One-way ANOVA P values among obese groups (far-right). Dunn’s Multiple Comparison test results for obese group:
aP < 0.05 vs. normal
bP < 0.01 vs. normal
cP < 0.05 vs. SS
doi:10.1371/journal.pone.0142676.t004
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Comparing African Americans and Caucasians with SS
Despite having higher BMI’s and insulin resistance measured by HOMA2-IR compared to
Caucasians with SS, the African American women with SS had decreased triglycerides and liver
enzymes (Fig 2A–2C). African Americans with SS had lower total VLDL and all sub-fractions
(Fig 2D) and decreased total and small LDL compared to Caucasians (Fig 2E). African Ameri-
cans also had improved HDL profiles as evidenced by increased large HDL and less small HDL
particle numbers compared to Caucasians with SS (Fig 2F). Further, Caucasians with SS had a
much higher LP-IR score than African Americans with SS (Table 6).
Table 5. Lipid and lipoprotein measures in class III obese Caucasian females stratified by histology.
Variable Obese Normal Obese SS Obese NASH P-value
n 13 11 17
HOMA2-IR 2.5 ± 0.3 2.0 ± 0.5 3.6 ± 0.5d 0.004
Insulin 18.6 ± 1.9 17.2 ± 4.1 28.8 ± 3.8d 0.006
Glucose 95.1 ± 3.0 98.0 ± 4.5 109.8 ± 6.2 0.099
NMR calculated lipids
Triglycerides (mg/dL) 136.5 ± 15.8 195.5 ± 19.2a 168.2 ± 9.9 0.034
HDL cholesterol (mg/dL) 42.8 ± 2.6 46.4 ± 3.7 44.8 ± 1.8 0.427
VLDL & chylomicron TG (mg/dL) 102.7 ± 16.5 152.7 ± 17.2 136.8 ± 10.2 0.0651
Lipoprotein particles
TOTAL VLDL (nmol/L) 65.3 ± 10.3 81.6 ± 8.7 72.48 ± 5.6 0.895
Large VLDL & chylomicrons 5.8 ± 1.2 11.2 ± 1.4b 10.4 ± 1.0b 0.006
Medium VLDL 28.0 ± 6.8 31.1 ± 6.0 25.3 ± 2.8 0.736
Small VLDL 31.5 ± 4.4 39.2 ± 5.7 36.7 ± 3.2 0.472
TOTAL LDL (nmol/L) 1241 ± 84 1636 ± 117 1157 ± 101c 0.014
IDL 114 ± 22 173 ± 41 102 ± 15 0.377
Large LDL 417 ± 68 443 ± 85 264 ± 62 0.076
Small LDL 708 ± 98 1019 ± 119 789 ± 75 0.228
TOTAL HDL (μmol/L) 31.6 ± 1.5 35.5 ± 2.6 35.3 ± 1.4 0.264
Large HDL 4.0 ± 0.6 3.6 ± 0.6 3.6 ± 0.4 0.815
Medium HDL 6.4 ± 1.1 6.1 ± 1.1 7.2 ± 1.1 0.899
Small HDL 19.3 ± 1.2 22.7 ± 2.2 21.6 ± 1.4 0.311
ApoB100 (mg/dL) 111.5 ± 4.7 131.0 ± 7.6 103.6 ± 6.1c 0.020
Lipoprotein particle size (nm)
VLDL 50.6 ± 1.4 57.0 ± 1.9b 57.3 ± 1.0b 0.002
LDL 20.5 ± 0.2 20.4 ± 0.2 20.2 ± 0.1 0.182
HDL 8.9 ± 0.1 8.7 ± 0.08 8.9 ± 0.09 0.497
Particle ratios
LDL small/large ratio 3.7 ± 1.2 5.9 ± 3.0 5.6 ± 1.1 0.511
HDL small/large ratio 5.7 ± 0.9 6.6 ± 0.6 7.2 ± 0.9 0.459
Lipoprotein Insulin Resistance Score 45.9 ± 6.4 56.6 ± 7.2 73.4 ± 4.7a 0.027
Data presented as mean ± SEM. AU, arbitrary units. P values represent difference between groups.
aP < 0.05 vs. normal
bP < 0.01 vs. normal
cP < 0.05 vs. SS
dP < 0.01 vs. SS
doi:10.1371/journal.pone.0142676.t005
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Discussion
This study in a controlled population of histologically proven NAFLD identified novel changes
in fasting lipoprotein subclass particle number and size that delineated simple steatosis from
NASH. Namely, we found that circulating VLDL particle number, VLDL size, and TG content
were increased in SS relative to weight-matched obese normal females, whereas NASH females
trended toward decreased VLDL with significant declines in LDL particle number and
apoB100 concentrations compared to SS. We also identified disparities in the relationship
between lipoprotein profiles and NAFLD in African American women relative to Caucasians.
The relationship parallels the differential prevalence of dyslipidemia across ethnicities and may
explain the variation in studies of NAFLD epidemiology and dyslipidemia in the literature to
date [9]. These findings suggest a role for monitoring lipoprotein profiles in NAFLD progres-
sion, but that ethnicity should be considered in the process [33].
Table 6. Lipid and lipoprotein measures in class III obese African American females stratified by histology.
Variable Obese Normal Obese SS P-value
n 5 5
HOMA2-IR 2.2 ± 0.5 3.4 ± 0.6 0.222
Insulin 18.7 ± 4.8 26.6 ± 5.2 0.530
Glucose 99.8 ± 5.2 113.6 ± 18.9 0.917
NMR calculated lipids
Triglycerides (mg/dL) 77.0 ± 11.5 80.0 ± 7.7 0.401
HDL cholesterol (mg/dL) 51.2 ± 6.5 60.2 ± 10.2 0.802
VLDL & chylomicron TG (mg/dL) 42.96 ± 8.6 41.72 ± 5.1 0.667
Lipoprotein particles
TOTAL VLDL (nmol/L) 22.66 ± 5.4 27.5 ± 3.5 0.421
Large VLDL & chylomicrons 2.3 ± 0.8 2.3 ± 0.7 0.917
Medium VLDL 8.5 ± 2.0 7.2 ± 2.0 0.841
Small VLDL 11.8 ± 4.1 18.0 ± 4.4 0.421
TOTAL LDL (nmol/L) 1026 ± 168 1191 ± 139 0.691
IDL 103 ± 27 74 ± 16 0.548
Large LDL 555 ± 184 694 ± 131 0.691
Small LDL 367 ± 180 422 ± 155 0.841
TOTAL HDL (μmol/L) 31.8 ± 1.6 36.1 ± 3.0 0.295
Large HDL 7.4 ± 1.7 8.5 ± 2.3 0.737
Medium HDL 9.3 ± 2.6 8.5 ± 2.3 0.691
Small HDL 13.04 ± 2.5 17.4 ± 1.4 0.310
ApoB100 (mg/dL) 92.6 ± 12.5 98.4 ± 13.4 0.472
Lipoprotein particle size (nm)
VLDL 49.5 ± 2.7 48.0 ± 4.8 0.714
LDL 20.6 ± 0.3 21.1 ± 0.2 0.139
HDL 9.5 ± 0.2 9.4 ± 0.2 0.325
Particle ratios
LDL small/large ratio 5.3 ± 4.6 0.9 ± 0.4 0.366
HDL small/large ratio 2.9 ± 1.4 2.7 ± 0.6 0.916
Lipoprotein Insulin Resistance Score 33.8 36.2 0.397
Data presented as mean ± SEM. AU, arbitrary units.
doi:10.1371/journal.pone.0142676.t006
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Fig 2. Ethnic Lipoparticle Comparisons. African American women with simple steatosis had less atherogenic lipoprotein profiles relative than Caucasian
women with simple steatosis. A) African Americans with simple steatosis (SS) were heavier (*P<0.05) and more insulin resistantB) as measured by
homeostatic model assessment index 2 (HOMA2-IR, *P<0.05), yet displayed lower triglycerides (***P<0.001, not shown) andC) lower alanine
aminotransferase (ALT, *P<0.05) than Caucasian SS.D) African Americans with SS displayed lower total very-low-density lipoprotein (VLDL) and VLDL
sub-fractions (**P<0.01 for all, except small VLDL particle concentration, *P<0.05), E) decreased total and small low-density lipoprotein (LDL; *P<0.05 and
**P<0.01, respectively), and F) improved high-density lipoprotein (HDL) profiles (increased large HDL, p = 0.002, and lower small LDL, P = 0.04) relative to
Caucasian SS (E-F). Values are mean ± SEM. Data were analyzed by one-way ANOVA, followed by Mann-Whitney t Tests.
doi:10.1371/journal.pone.0142676.g002
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Individual lipoprotein parameters such as increased small LDL, small HDL, and ApoB100
have been associated with increased atherogenic risk and diabetes independent of obesity, but
less is known about lipoprotein characteristics relative to NAFLD progression [28, 29, 34–36].
Given the liver is the site of a majority lipoprotein secretion and uptake, namely VLDL and
LDL, alterations in lipoprotein profiles may reflect changes in NAFLD progression [1, 37–40].
Studies using imaging such as CT or MRI [10] to diagnose NAFLD found that the lipoprotein
profile changes accompanying NAFLD are similar to the dyslipidemia that precedes the onset
of T2D including increased triglycerides, large VLDL, VLDL size, and small LDL, and
decreased large HDL [5, 12–14, 18]. Further, they found that triglycerides and total cholesterol
increase and HDL decreases with hepatic fat. However, these studies were insufficient to
describe NASH, as only liver biopsy can detect the inflammation, fibrosis, and ballooning that
distinguish NASH from steatosis [9, 32, 41, 42]. Other studies have evaluated lipoprotein using
AST and ALT as surrogate markers of hepatic dysfunction, but these enzymes are normal in up
to 78% of patients with NAFLD and thus cannot be used to accurately diagnose the disease or
distinguish steatosis from NASH [20–22].
Of the studies in biopsy confirmed NASH, plasma lipoparticle analyses by HPLC or ultra-
centrifugation have shown an increase in total triglycerides, VLDL, LDL, and ApoB100 and a
decrease in HDL in NASH relative to normal livers [4]. Studies of steatosis versus NASH how-
ever have been less congruent, as some show decreases in VLDL (and HDL), and others an
increase. Recently, the use of NMR-derived lipoprotein profiles revealed previously undetected
changes in particle number and size that are associated with metabolic disease [34]. We are
only the second study to employ this technology to compare biopsy driven NAFLD diagnoses
to lipoprotein profiles [43]., but this other work did not use the standard subclass classifications
employed by the existing literature and available commercial methods [25], thus limiting its
applicability [24]. In addition, the group did not report differences between SS and NASH,
only differences relative to normal histology, nor did they stratify their cohort by ethnicity or
gender. Similar to ethnicity, the relationship between dyslipidemia and metabolic diseases such
as diabetes, cardiovascular disease, and NAFLD differs by gender, with females displaying
improved lipid profiles relative to men [11, 44]. Hence, the study may have missed significant
differences in lipoprotein subclass profiles across pathology due to cohort heterogeneity.
In this study we found that changes in steatosis versus NASH were most pronounced when
Caucasian women were examined alone. Among Caucasians, increased VLDL size and TG
content were the first changes associated with the development of NAFLD, similar to other in
ethnically heterogeneous reports [15, 16, 45]. Here progression from SS to NASH was accom-
panied by more global dysfunction, with decreased total LDL and apoB100 production and
increased insulin resistance. These findings suggest a role for deranged lipid production in dis-
ease progression, in particular ApoB100 [15, 16, 46]. ApoB100 is a lipid-binding protein pro-
duced in the liver that is necessary for the assembly and secretion of VLDL [39]. Because one
apoB100 is required for each VLDL particle, its availability determines hepatic lipoprotein pro-
duction, thus deficiency in the protein synthesis or release could contribute to hepatic TG
retention [5]. Fujita et al. came to a similar conclusion when they found that VLDL and
ApoB100 mRNA was decreased in NASH relative to simple steatosis patients, but they found
that LDL was increased. However, they did not evaluate lipoprotein parameters via H-NMR
nor did they stratify their results by gender, both of which might explain the different results
[16].
In addition to the decline in lipoprotein parameters in NASH, we found differences in
demographics and lipid profiles between African Americans and Caucasian women with SS.
Here none of the African American women had NASH. This is similar to the epidemiological
literature which reports decreased rates of NAFLD and NASH among African Americans, an
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observation that has been attributed to variation in genetics and body fat distribution [47]. We
found that African Americans with SS weighed more and were more insulin resistant than
Caucasians with SS, yet had a less atherogenic lipid profile. This reflects the “triglyceride para-
dox” of improved dyslipidemia in African Americans relative to other ethnicities despite higher
rates of obesity and insulin resistance [48]. Attempts to explain this discrepancy have impli-
cated increased lipoprotein lipase (LPL) activity and lower levels of the LPL inhibitory protein,
apolipoprotein CII, in African Americans as a cause [47, 49] as well as an apoB100 gene variant
that is associated with VLDL diameter in Caucasians and Hispanics, but not African Ameri-
cans [50]. While the mechanisms are yet to be elucidated, these findings point to potential eth-
nic differences in hepatic lipid metabolism [44, 47, 50].
A final novel facet of this study was the use of the lipoprotein-insulin resistance (LP-IR)
score to quantify the relationship between dyslipidemia and insulin sensitivity. The importance
of lipids in the pathogenesis of insulin resistance has been highlighted by Randle et al. who
described a glucose-fatty cycle where increased byproducts of lipid oxidation lead to inhibition
of glucose uptake in type I diabetics [26]. Other studies utilizing H-NMR techniques found sig-
nificant associations between lipoprotein profile constituents and insulin sensitivity [28, 29].
Six parameters in particular have been used to create an overall picture of insulin resistance
known as the LP-IR Score [26, 30]. Here we found a positive relationship between LP-IR and
HOMA2-IR including a significant increase in NASH females. Further, increases in LP-IR in
Caucasians accompanied or preceded increases in HOMA2-IR and were associated with pro-
gression to NASH. Given dyslipidemia’s tendency to precede the onset of frank diabetes, the
LP-IR score and the lipocentric view of insulin resistance might be of use in the early identifica-
tion of T2D or NASH [5], but additional studies are needed to further validate this new
technique.
This study has some limitations. While liver biopsy remains the “gold standard” for assess-
ing NAFLD severity, the procedure carries risk and therefore was not available for all females
[19]. This also rendered our study cohort smaller than those used in larger population-driven
studies. Our African American population is especially small, but is reflective of the larger bar-
iatric surgery population, which is currently predominately Caucasian [51, 52]. This work
should be repeated in a larger, ethnically diverse cohort of both sexes. Similar to ethnicity, dif-
ferences in NAFLD severity and dyslipidemia are described in males versus females, thus our
decision to recruit only females [53]. Other considerations include more detailed analysis of
insulin resistance via hyperinsulinemic euglycemic clamp or lipoprotein production via tracer
studies. It would also be useful to assess liver histology longitudinally, but unfortunately, non-
clinically indicated liver biopsies are rarely warranted based on ethical concerns.
In conclusion, this study identified differences in total lipoprotein and subclass levels across
NAFLD severity that differed in Caucasians versus African American women. The combina-
tion of NMR lipoprotein analysis and biopsy driven NASH diagnoses provided the opportunity
to appreciate previously undetected changes in lipoprotein profiles, namely changes in VLDL,
LDL, and apoB100 that can be used to delineate steatosis from NASH in Caucasian women.
These findings suggest a potential role for lipoprotein subclass concentration and size as mark-
ers of NAFLD progression, particularly apoB100. Monitoring for relative reductions in these
parameters, as well as changes in the LP-IR index, may enable clinicians to better identify and
monitor those at increased risk for developing NASH. However, if this strategy is to be
employed clinically, our observations in African Americans with SS highlight the need for sep-
arate parameters for each ethnicity, as the relationship between dyslipidemia and NAFLD does
not appear to be racially homogenous.
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